We can’t show the full text here under this license.
Stomach and digestion side effects of non-peptide GLP-1 receptor drugs: A combined study review
Updated
Abstract
Essence
A systematic review and meta-analysis found that oral non-peptide commonly caused gastrointestinal side effects, especially nausea.
Evidence
Systematic review and meta-analysis of 4 studies of oral danuglipron and orforglipron, with nausea the most common event and odds ratios for nausea ranging from 3.69 to 5.66 across reported doses.
Caveat
The analysis covers only 4 studies, and the abstract reports elevated odds ratios while also stating side effects were less frequent than placebo standard treatment, making the comparative interpretation unclear.
Simplified
Key numbers
5.66
Increase in Nausea ()
for nausea at the 24 mg dose of orforglipron
4.41
Increase in Nausea ()
for nausea at the 45 mg dose of orforglipron
less frequent than placebo
Decrease in Gastrointestinal Side Effects
Comparison of side effects of non-peptide GLP-1 RA to placebo